Editorial - Moving forward on the pathway of targeted immunotherapies for type 1 diabetes: the importance of disease heterogeneity

Eur Rev Med Pharmacol Sci. 2019 Oct;23(19):8702-8704. doi: 10.26355/eurrev_201910_19188.

Authors

M Infante^{1

2

3}, C Ricordi^{1

2}

Affiliations

¹ Diabetes Research Institute (DRI), University of Miami Miller School of Medicine, Miami, FL, USA. marcoinfante.md@gmail.com.
² Diabetes Research Institute Federation (DRIF), Miami, FL, USA
³ Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy

PMID: 31646605
DOI: 10.26355/eurrev_201910_19188

No abstract available

Publication types

Editorial

MeSH terms

Diabetes Mellitus, Type 1 / immunology
Diabetes Mellitus, Type 1 / pathology
Diabetes Mellitus, Type 1 / therapy*
Humans
Immunotherapy*